Cart
sales@molnova.com
Tyrphostin A1
CAS No. 2826-26-8
Tyrphostin A1( Tyrphostin 1 | AG9 )
Catalog No. M20945 CAS No. 2826-26-8
Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 27 | In Stock |
|
| 10MG | 42 | In Stock |
|
| 25MG | 80 | In Stock |
|
| 50MG | 113 | In Stock |
|
| 100MG | 147 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTyrphostin A1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
In Vitro——
-
In Vivo——
-
SynonymsTyrphostin 1 | AG9
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2826-26-8
-
Formula Weight184.19
-
Molecular FormulaC11H8N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (542.92 mM)
-
SMILESCOc1ccc(C=C(C#N)C#N)cc1
-
Chemical Name2-[(4-Methoxyphenyl)methylidene]propanedinitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Du C Bright J J Sriram S . Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice[J]. Journal of Neuroimmunology 2001 114(1-2):69-79.
molnova catalog
related products
-
PF 6274484
PF 6274484, a high affinity, irreversible covalent inhibitor of EGFR kinase with Ki of 0.14 nM.
-
Befotertinib
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
